Switching from originator infliximab to biosimilar CT-P13 compared with maintained treatment with originator infliximab (NOR-SWITCH): a 52-week, randomised, double-blind, non-inferiority trial - The Lancet
NOR-SWITCH
Efficacy and Safety of CT-P13 in Inflammatory Bowel Disease after Switching from Originator Infliximab: Exploratory Analyses from the NOR-SWITCH Main and Extension Trials | BioDrugs
Long‐term efficacy and safety of biosimilar infliximab (CT‐P13) after switching from originator infliximab: open‐label extension of the NOR‐SWITCH trial - Goll - 2019 - Journal of Internal Medicine - Wiley Online Library
Source no need to set up, install driver, nor switch 4g dongle with sim card on m.alibaba.com
NOR-SWITCH' Paper Explores Impact Of Biosimilar Switching Research